Beruflich Dokumente
Kultur Dokumente
Technical Bulletin
Key Points :
Vaccine formulations with MONTANIDE ISA 760 VG induce a strong and long
tolerated vaccines
TM
ISA 760
1. VACCINE PREPARATION:
To prepare 100 g of vaccine, a typical composition is recommended:
MONTANIDE ISA 760 VG:
70 g
Aqueous antigenic medium:
30 g
TYPE
VISCOSITY
(mPa.s)
W/P
(water-inpolymer)
About 40
at 25C
1 or less
After storage at
4C
At least 12 months
TYPICAL STABILITY
After storage at
25C
After storage at
37C
At least 6 months
About 15 days
TM
3. IMMUNE RESPONSE: MONTANIDE ISA 760 VG is capable of improving vaccine efficacy via the induction of a strong
and long lasting immunity. Its a promising adjuvant to stimulate humoral responses. This product is recommended
for bacterial, mycoplasma, viral or parasite antigens.
4. ANIMAL SPECIES:
poultry and fish.
MONTANIDE ISA 760 VG adjuvant is recommended for different vaccines for cattle, swine,
5. STRENGTH: This adjuvant is a flexible and robust formulation. It is adapted to prepare water-in-polymer
emulsions, which induce a strong efficacy similar to oil emulsions. Furthermore it offers the possibility to reduce the
injected dose or to dilute antigenic media with a constant injected volume while keeping the same level of protection.
TM
6. SAFETY AND REGULATORY: The toxicological tests made on MONTANIDE ISA range (Berlin test, Oral LD 50, IP LD 50,
ocular irritation test, dermal irritation test, pyrogenicity) conclude to the safety and favourable tolerance of these
adjuvants.
Montanide adjuvants and their components have been considered as safe by the Committee for Veterinary Medical
Products (CVMP) for use in immunological products and are included as authorized substances in the annex of the
European Council Regulation n 470/2009 (previously 2377/90/EC) needing no further MRL studies, or included in
already registered veterinary commercial products.
The properties of the antigenic media are crucial for the vaccine efficacy but also for its safety. Each team developing a
vaccine will have to study the safety and efficacy profile of the underdevelopment formula according to local market
acceptance criteria.
For more information on this product or for any advice regarding the optimization of your vaccine,
please contact our teams on www.seppic.com or on Montanide@airliquide.com
SEPPIC Inc
33(0) 1 42 91 40 00
Givaudan-Lavirotte SA
33(0) 4 78 61 55 00
SEPPIC China
86(21) 64 66 01 49
www.seppic.com
Subsidiary of the AIR LIQUIDE group
SEPPIC UK Ltd
39 02 38009110
SEPPIC GmbH
49(0) 220 3890 3100
SEPPIC Belgium NV
32 3 250 3911
3637/GB/01/August 07
SEPPIC SA